Inquis Medical’s AVENTUS Thrombectomy System has received 510(k) clearance from the FDA for an expanded indication to treat pulmonary embolism.
AVENTUS Trial evaluating safety and efficacy of Inquis Medical’s AVENTUS Thrombectomy System met primary endpoints, results presented today at SCAI.
MENLO PARK, Calif. — January 13, 2025 — Inquis Medical, a leading innovator in venous thromboembolic disease treatment, today announced completion of patient enrollment in
A case example highlights the function of the AVENTUS System for the removal of emboli and
thrombi for the treatment of pulmonary embolism.
MENLO PARK, Calif.–(BUSINESS WIRE)–Inquis Medical, a pioneering medical technology company specializing in advanced thrombectomy systems, today announced the successful closure of its $40 million Series
What are the key unmet needs with current pulmonary embolism (PE) thrombectomy devices? Dr. Shishehbor: Despite the many advances in the treatment of PE, it
AVENTUS Thrombectomy System
Indications for Use: The AVENTUS Thrombectomy System is indicated for:
The AVENTUS Thrombectomy System is intended for use in the peripheral vasculature.
The AVENTUS Clot Management System is indicated for use with the AVENTUS Thrombectomy System for autologous blood transfusion.
AVENTUS Thrombectomy System
Indications for Use: The AVENTUS Thrombectomy System is indicated for:
The AVENTUS Thrombectomy System is intended for use in the peripheral vasculature.
The AVENTUS Clot Management System is indicated for use with the AVENTUS Thrombectomy System for autologous blood transfusion.
